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O-glicosilação, antigénios associados ao antigénio Thomsen-
Friedenreich, cancro da bechiga, lesões precursoras do cancro gástrico, 
MALDI, ácidos siálicos, permetilação 
Resumo          Uma das alterações fenótipicas mais comuns nos tumores são 
modificações no padrão de O-glicosilação na superfície da célula e nas 
glicoproteínas secretadas. Como consequência têm implicações nas suas 
funções biológicas. Em particular, tem sido descrito que algumas células 
tumorais sobreexpressam ou expressam de novo antigénios associados ao 
antigénio Thomsen-Friedenreich (TF), ou seja, sialil-Tn, sialil-T e 
disialyl-T. Estes epítopos resultam da paragem prematura do processo de 
O-glicosilação em proteínas e têm um impacto direto sobre a biologia do 
tumor. Assim sendo, a identificação destas modificações pós-
translacionais  anormais em proteínas é essencial para determinar as 
relações estrutura-função e descobrir novos alvos terapêuticos. Além 
disso, as proteínas que transportam estas alterações podem ser secretadas 
na corrente sanguínea,  urina, e em outros fluidos corporais e, portanto, 
são explorados como biomarcadores em testes não invasivos. 
Atualmente a detecção de antigénios associados ao antigénio TF é 
baseado em métodos imunohistoquímicos em que, embora úteis para 
uma investigação de rotina, não conseguem descrever totalmente o 
padrão de glicosilação de uma dada proteína. Sendo assim, neste 
trabalho apresentamos uma abordagem analítica para determinar estes 
glicanos em quantidades minimas de glicoproteínas (picomole) isoladas 
a partir de géis SDS-PAGE. Resumidamente, as glicoproteínas são de-O-
glicosiladas no gel por beta-eliminação redutiva, permetiladas e 
analisadas por nanoLC-MALDI-TOF/TOF. De seguida, os dados 
provenientes são sujeitos a uma seleção melhorada dos sinais analíticos 
relevantes, utilizando ferramentas de bioinformática. Esta abordagem 
foi, em seguida, aplicada com sucesso na validação do western blotting 
quanto à expressão de sialil-Tn numa glicoproteína isolada a partir da 
urina de ratos com tumores na bexiga induzidos quimicamente e no 
plasminogénio isolado a partir do soro de pacientes com lesões 
precursoras do cancro gástrico. 
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Abstract         A common phenotypic change in tumors comprises alterations in the 
O-glycosylation of cell-surface and secreted glycoproteins with 
implications in their biological functions. In particular, it has been 
described that some tumor cells overexpress or de novo express 
Thomsen-Friedenreich (TF)-related antigens, namely sialyl-Tn, sialyl-T 
and disialyl-T. These epitopes result from a premature stop in protein O-
glycosylation and have direct impact on tumor biology. As a result, the 
identification of these abnormal post-translational modifications of 
proteins is essential to determine structure-function relationships and 
designs novel therapeutics. Moreover, the proteins carrying these 
alterations can ultimately be shed into the blood stream, urine and other 
body fluids and thus be explored as biomarkers in non invasive tests. 
Currently the detection of TF-related antigens relies on immuno-based 
methods that, even though useful in a routine basis, often fail to fully 
highlight the glycosylation pattern of a given protein. Herein, we have 
systematized a target-driven analytical approach to determine these 
glycans in minute amounts of glycoproteins (picomole) isolated from 
SDS-PAGE gels. Briefly, the glycoproteins are to be de-O-glycosylated 
in-gel by reductive beta-elimination, permethylated and analyzed by 
nanoLC-MALDI-TOF/TOF with enhanced selection of the relevant 
analytical signals using bioinformatics tools. This approach was then 
successfully applied to validate western blotting assignments regarding 
the expression of sialyl-Tn in a glycoprotein isolated from the urine of 
rats with chemically-induced bladder tumors and in plasminogen isolated 
from the serum of patients with gastric cancer precursor lesions.  
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Abbreviations  
 
β4/3GalTs - β1,-4/3 Galactosyltranferases 
β3/4GnTs - β1-3/4 N-acetylglucosaminyltransferases 
C1GalT - Core 1 β1-3 Galactosyltransferase or T synthase 
C2GnT - Core 2 β1-6 N-acetylglucosaminyltransferase 
C3GnT - Core 3 β1-3 N-acetylglucosaminyltransferase 
CID- Colision induced dissocation 
CMP-Neu5Ac - Cytosine monophosphate N-acetyl neuraminic acid 
Cosmc - Core 1 β1-3galactosyltranferase-specific molecular chaperone 
ER - Endoplasmic Reticulum 
Fuc – Fucose 
Gal - Galactose 
GalNAc – N-acetyl-galactosamine 
GlcNAc - N-acetyl-glucosamine 
HexNAc - N-acetyl-hexosamine 
MALDI - Matrix-assisted laser desorption/ionization 
MS- Mass spectrometry 
Neu5Ac – N-acetyl-neuraminic acid  
ppGalNAc-Ts - polypeptide N-acetylgalactosaminyltransferases  
Pro – Poline 
PTM - post-translational modification 
Ser - Serine   
ST3Gal - α 2-3 Sialyltransferases galactosamine 
ST6GalNAc - α 2-6 Sialyltransferases N-acetylgalactosamine   
Thr – Threonine 
TOF - Time of flight  
UDP-Gal - Uridine diphosphate - galactosamine   
UDP-GalNAc - Uridine diphosphate - N-acetylgalactosamine   
UDP-GlcNAc - Uridine diphosphate - N-acetylglucosamine   
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1. Introduction 
Glycosylation is one of the most ubiquitous and complex post-translational 
modification (PTM) and is estimated to occur on more than half of the proteins encoded in 
eukaryotic human genomes [1]. The glycosylation of mammalian proteins is achieved by 
the action of glycosyltransferases, that catalyze the transfer of a sugar from a donor 
molecule to the a potential site of polypeptide or carbohydrate [2]. During malignant 
transformation of the cell this “glycosylation machinery” is significantly compromised. 
Such changes have been explained by either a disorganization of secretory pathway 
organelles (Endoplasmic reticulum and Golgi apparatus) and/or altered glycosyltransferase 
expression [3]. A deregulation in fine tuning of this “glycosylation machinery” has direct 
impact in the cell biological behavior, namely its adhesion, signaling properties, and 
interaction with the immune system [4]. Among the most common alterations in O-
glycosylation is the expression of short oligosaccharide chains, the Thomsen- 
Friedenreich(TF)-related antigens. This low molecular weight glycans result from a 
premature stop in biosynthesis of O-glycans, leading to the formation of Tn (GalNAcα-O-
Ser/Thr) and T (Galβ1-3GalNAcα-O-Ser/Thr) antigens. Tn an T antigens are precursors for 
many complex structures, that ultimately can be terminated with Lewis and blood group 
determinants [5]. In the presence of specific sialyltransferases they may form their 
sialylated-counterparts, sialyl Tn (Neu5Acα2-3GalNAcα-O-Ser/Thr), sialyl-T (Neu5Acα2-
3Galβ1-3GalNAcα-O-Ser/Thr), sialyl-6-T (Galβ1–3(NeuAcα2-6)GalNAcα-O-Ser/Thr) and 
disialyl-T (NeuAcα2-3Galβ1-3[NeuAcα2-6]GalNAcα-O-Ser/Thr). T-related antigens are 
also classically referred to as simple mucin type carbohydrates, since they are abundantly 
expressed in mucins due to the high density of  O-glycosylation sites [3].  
Sialylated TF-related antigens are generally expressed in low levels or not 
expressed at all in healthy tissues; yet they are frequently (over)expressed in several human 
malignancies [6]. The sialyl-Tn is the most studied epitope due its overexpression and de 
novo biosynthesis in several cancers, including gastric tumors [7]. Thereby it may be 
considered as a hallmark of cancer cell transformation, correlating with poor prognosis, 
poor outcome, aggressiveness and metastization [2, 3, 5]. As a result it has been targeted 
for immunotherapy and explored both as a biomarker and in cancer vaccines [8]. The 
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Sialyl-T and disialyl-T are commonly expressed in the healthy human epithelium, but still 
overexpressed in some malignancies, such as bladder tumors [9].  
The role of the sialylated TF-related antigens, in particular sialyl-Tn, in human 
health and disease has been a hot topic over the last twenty to thirty years and regarded of 
great interest for carbohydrate-based vaccines, drug development and diagnosis [10]. The 
complexity of these glycans and its association with proteins, makes of structural 
characterization a key part of in the context of research. Nowadays mass spectrometry 
(MS) has proven to be the core technology behind proteomics, and it stands to play a 
similar role in the study of the functional implications of carbohydrate expression [11, 12]. 
Mass spectrometry may provide insights on the purity, molecular mass, monosaccharide 
composition, sequence of sugar residues, presence and position of branches, inter-
glycosidic linkages and isomeric molecules [13]. In particular, matrix-assisted laser 
desorption/ionization (MALDI), is a soft ionization technique with high sensitivity, 
resolution and suitable for small amounts of sample. Even though widely used in 
proteomic research, MALDI ionization is known to transfers high energy to labile 
compounds, such as sialic acids, promoting their fragmentation [14, 15]. This has been 
mostly overcome by derivatization approaches such as permethylation, that provides an 
increase ionization response allowing their detection in the positive mode [12, 16-18]. 
Moreover, it provides highly informative product ion spectra that may allow a full 
assignment of the primary structure, including the distinction of isomers [19]. However, 
the high pH used in permethylation promotes a significant degree of oxidative degradation 
and peeling reactions [20, 21]. Undesirable by-products are also promoted by the high pH, 
reductive environment and the temperature necessary for the de-O-glycosylation of 
proteins in the absence of specific O-glycosidases. This synergism of factors is responsible 
by the introduction of significant background noise and, in some extent, the degradation of 
the glycans under analysis [22]. As such, the analysis by MALDI of sialylated TF-related 
antigens, having as starting material low picomole to femtomole of a given glycoprotein, is 
currently regarded as major analytical challenge.  
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2. Structure and biosynthesis of O-GalNAc glycans in mammalian cells 
The biosynthesis of the carbohydrate structures in glycoproteins relies on a number 
of competitive and very concerted processes involving several glycosyltransferases. Mucin 
(GalNAc)-type O-glycosylation (here called O-glycosylation) is one of the most common 
type of glycosylation found in glycoproteins and consists of a glycan O-linked to a serine 
(Ser) or a threonine (Thr) residue. The association of this type of glycosylation with 
mucins results from the high density of Ser/Thr/Pro domains encountered in this heavily 
glycosylated class of protein [23].  
The first step of O-glycosylation involves the transfer of N-acetyl-galactosamine 
from a sugar donor UDP-GalNAc on to serine or threonine residue of a given polypeptide 
chain. This step is controlled by the activity of polypeptide N-acetyl-
galactosaminyltransferases (ppGalNAc-Ts) and results in the formation of the Tn antigen 
(GalNAcα-O-Ser/Thr; Figure 1 and Table 1). Until now at least twenty one ppGalNAc-Ts 
isoforms have been identified in mammals [24, 25]. These class of enzymes determine 
both O-GalNAc sites and density of glycosylation [26] and are characterized by different 
tissue expression [27], kinetic properties and acceptor substrate specificities [28, 29]. All 
ppGalNAc-Ts bind UDP-GalNAc, but ppGalNAc-Ts are known to have high overlapping 
substrate specificity and many substrates are modified by several ppGalNAc-Ts [30].  
The addition of the first GalNAc sugar into a region rich in Ser/Thr of the protein, 
changes the way other ppGalNAc-T isoforms act [31]. As such,  the competition between 
ppGalNAc-Ts can cause different patterns of O-glycosylation. Therefore, the multiplicity 
of ppGalNAc-T isoforms fine-tunes the pattern and density of GalNAc modification on 
proteins, that are highly enriched in acceptor sites. Thus, co-expression in the same cell of 
ppGalNAcTs with complementary, partly overlapping acceptor substrate specificities 
probably ensures efficient O-GalNAc glycosylation [32]. After the first step of 
glycosylation, the Tn antigen can be prematurely terminated by sialylation when increased 
levels of ST6GalNAc-I/II are present. These enzymes are responsible by the transfer of a 
N-acetyl-neuraminic acid (Neu5Ac) from cytosine monophosphate N-acetyl-neuraminic 
acid (CMP-Neu5Ac) to the O-6 position of the GalNAc residue of a Tn antigen, thus 
originating the sialyl-Tn antigen (Neu5Acα2-6GalNAcα-O-Ser/Thr; Figure 1) [33]. The 
sialylation of the Tn antigen can be performed by two different isoforms of ST6GalNAc, 
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which are ST6GalNAc-I and ST6GalNAc-II. Still  it has been demonstrated that, when the 
Tn and T antigens are present in vitro essays, ST6GalNAc-I acts preferentially on Tn 
antigen [34].  
Despite these observations, in most mammalian tissues, the Tn antigen is a 
substrate for core 1 β1-3 galactosyltransferases (C1GalT) or T synthase. The formation of 
the active core 1 β1-3 galactosyltransferase in vivo is dependent on core 1 β1-3 
galactosyltransferase-specific molecular chaperone (Cosmc) [35]. Cosmc is an 
Endoplasmic Reticulum (ER) protein that appears to bind specifically to T synthase and 
ensures its full activity in the Golgi Apparatus [36]. C1GalT catalyzes the transfer of a Gal 
from uridine diphosphate-galactose (UDP-Gal) to the O-3 position of GalNAc residue, 
generating the core 1 or T antigen (Galβ1-3GalNAcα-O-Ser/Thr; Figure 1 and Table 1). 
The T antigen can also be prematurely ended by sialylation. Unlike for sialyl-Tn,  the 
sialylation of the T antigen is mostly mediated by α2-3 sialyltransferases, namely ST3Gal-I 
or ST3Gal-II [37]. The pointed out enzymes are responsible by the addition of a Neu5Ac 
from the sugar donor CMP-Neu5Ac to the O-3 position of the Gal residue of core 1 
originating sialyl-3-T antigen (Neu5Acα2-3Galβ1-3GalNAcα-O-Ser/Thr, Figure 1). The 
sialyl-3-T antigen can be further sialylated by ST6GalNAC-I, II, III resulting in the 
disialylated-T antigen (Neu5Acα2-3Galβ1-3(Neu5Acα2-6)GalNAcα-O-Ser/Thr; disialyl-
T; Figure 1). On the other hand, the T antigen can also experience O-6 sialylation by either 
ST6GalNAc-I and/or ST6GalNAc-II, preferentially, ST6GalNAc-II, originating sialyl-6-T 
(Galβ1-3(Neu5Acα2-6)GalNAcα-O-Ser/Thr) [5, 38-40]. The above described low 
molecular weight O-GalNAc glycans and their sialylated counterparts are often present in 
tumor tissues as a result of a premature stop in glycosylation. This structures are 
commonly referred to as either simple mucin type O-glycans or T-related antigens [3]. 
Core 1 O-GalNAc is usually the starting point of much longer and more complex 
structures. Namely, the addition of a GlcNAc from UDP-GlcNAc to the O-6 position of the 
GalNAc residue by the core 2 β1-6-N-acetylglucosaminyltransferase (C2GnT) results in 
the formation of core 2 (GlcNAcβ1-6(Galβ1-3)GalNAcα-O-Ser/Thr;  Figure 1 and Table 
1) [41]. The C2GnTs present themselves in three isoforms, C2GnT-1, -2 and -3. The 
C2GnT-1/3, also known as leukocyte type (L type), is expressed in many tissues and 
synthesizes only the core 2. The C2GnT-2, also known as mucin type (M type) is found 
only in mucin-secreting cell types. This isoform is responsible for the synthesis of core 2 as 
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well as core 4 (GlcNAcβ1-6(GlcNAcβ1-3)GalNAcα-O-Ser/Thr; Figure 1 and Table 1) [41, 
42]. Conversely, in the presence of  core 3 β1-3-N-acetylglucosaminyltransferase (C3GnT) 
the Tn antigen can act as a precursor of core 3 (GlcNAcβ1-3GalNAcα-O-Ser/Thr; Figure 1 
and Table 1) that can further originate core 4. The core 4 (GlcNAcβ1-6(GlcNAcβ1-
3)GalNAcα-O-Ser/Thr; Figure 1 and Table 1) synthesis is accomplish by the action of M 
type β1-6-N-acetylglucosaminetransferase (C2GnT-2). This enzyme transfer GlcNAc from 
UDP-GlcNAc to the O-6 position of GalNAc [43]. The core 3 and branched core 4 O-
GalNAc glycans have been found only in secreted mucins of certain mucin-secreting 
tissues, such as intestinal mucus [23] and salivary glands [5, 44]. 
The extension of the O-GalNAc cores is achieved by the action of β1-4/3 
galactosyltranferases (β4/3GalTs) and β1-3/4-N-acetylglucosaminyltransferases 
(β3/4GnTs), Figure 1, which produces poly-lactosamine residues (Galβ1-4GlcNAcβ-), 
termed type II chains, or poly-neolactosamine residues (Galβ1-3GlcNAcβ-), termed type I 
chains. The elongated O-glycans can be further terminated by either Lewis and/or ABO 
blood determinants [45]. The O-glycan capping may also occur by the concerted addition 
of Neu5Ac through sialyltransferases (ST6Gal and ST3Gal), or by other molecules such as 
sulphate [5, 46]. 
 
 
Table 1.  Structures of O-GalNAc glycans cores. 
O-glycan cores Structure 
Core 1 or T antigen Galβ1-3GalNAcα-O-Ser/Thr 
 Core 2 GlcNAcβ1-6(Galβ1-3)GalNAcα-O-Ser/Thr 
 Core 3 GlcNAcβ1-3GalNAcα-O-Ser/Thr 
 Core 4 GlcNAcβ1-6(GlcNAcβ1-3)GalNAcα-O-Ser/Thr 
 Core 5 GalNAcα1-3GalNAcα-O-Ser/Thr 
 Core 6 GlcNAcβ1-6GalNAcα-O-Ser/Thr 
 Core 7 GalNAcα1-6GalNAcα-O-Ser/Thr 
 Core 8 Galα1-3GalNAcα-O-Ser/Thr 
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Cores 1-4 are the major cores expressed in human cells. Still, other core structures, 
such as core structures 5 to 8, have been observed, but are not so common in 
nature. Mucins with core 5 O-GalNAc glycans (GalNAcα1-3GalNAcα-O-Ser/Thr; Table 
1) have been reported in human meconium and intestinal adenocarcinoma tissue, whereas 
core 6 O-GalNAc (GlcNAcβ1-6GalNAcα-O-Ser/Thr; Table 1) is found in human 
intestinal mucin and ovarian cyst mucin. Core 8 O-GalNAc glycans (Galα1-3GalNAcα-O-
Ser/Thr; Table 1) has been reported in human respiratory mucin, while  bovine sub 
maxillary mucin may express core 7 O-GalNAc glycans (GalNAcα1-6GalNAcα-O-
Ser/Thr; Table 1) [23]. 
 
 
Figure 1. The biosynthetic pathway of O-GalNAc glycosylation and the action of competitive 
glycosyltransferases: polypeptide N-acetylgalactosaminyltransferases (ppGalNAc-Ts); sialyltransferases 
ST6GalNAc and ST3/ST6Gal; core 1 β1-3 galactosyltransferase (C1GalT); core 3 β1-3 N-
acetylglucosaminyltransferase (C3GnT); Core 2 β1-6-N acetylglucosaminyltransferase (C2GnT); 
fucosyltransferases (αFuc-Ts), β1-4/3 galactosyltranferases (β4/3Gal-Ts) and β1-3/4 N-
acetylglucosaminyltransferases (β3/4Gn-Ts). 
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3. Alterations at O-glycosylation level in tumors 
The pattern of protein glycosylation is cell and tissue specific [26] and closely 
reflects the physiological status of the cell. Thereby, changes in glycan expression are 
being observed for several pathological conditions and in particular in during malignancy 
(reviewed by Dabelsteen et al. (1996) [47]) . 
It is well established that changes in cellular O-glycosylation occur during 
malignant transformation, however, the functional significance of these alterations is less 
well understood [48]. Changes in carbohydrate core structure, increased synthesis of 
terminal structures, including Lewis blood group related antigens have been reported [47]. 
Indeed, glycan changes in malignant cells may assume a variety of forms, yet, the majority 
of the studies consensually report a high expression of incomplete O-glycans such as 
sialyl-Tn and other sialylated TF-related antigens [3]. Among the mechanisms leading to 
their expression are the up or down regulations of glycosyltransferases, re-localization of 
the enzymes, disorganization of secretory pathways, and metabolic alterations [5, 26].  
The sialyl-Tn is a pancarcinoma antigen which is aberrantly expressed in several 
epithelial tumors, including colorectal [49], ovarian [50], breast [51], pancreatic [52] and 
gastric carcinomas [7], while absent in the healthy mucosa [53]. The expression of sialyl-
Tn has been mostly connoted with the high expression of sialyltransferases, in particularly 
ST6GalNAc-I. In accordance with this observations, studies in carcinogenesis reported that 
this enzyme is weakly expressed in normal gastric mucosa [6]. On the other hand, Marcos 
et al (2004) showed that transfected gastric cells with ST6GalNAc-I expressed high levels 
of sialyl-Tn and this sialyltransferase is the major responsible for the its synthesis in vitro 
[34]. More recently ST6GalNAc-I was observed as the major enzyme controlling the 
expression of cancer-associated sialyl-Tn antigen in the gastrointestinal tissues[6]. 
The high expression of enzymes is not the only mechanism responsible for the 
(over)expression of sialyl-Tn. Several reports have been described a translocation of 
ST6GalNAc-I from later to early sub-compartments of the Golgi apparatus, as well as a 
blockage in the expression of core 1 and core 3. This phenomenon makes the Tn epitope 
available for sialyltransferases and thus leading the formation of sialyl-Tn. Another 
mechanism was explored in the genetic field that found mutations in Cosmc gene, that 
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encodes Cosmc, a molecular chaperone required for the activity of C1GalT. This mutation 
has been related with an enhanced synthesis of sialyl-Tn and Tn antigens [46, 53, 54].  
Given the overexpression or de novo expression of sialyl-Tn and its responsible  
mechanisms, this epitope has been associated with aggressiveness and metastatic potential 
of the epithelial carcinomas [55]. It is also a independent indicator of poor prognosis in 
gastric [56], ovarian [57] and colorectal cancer [58]. Regarding the biological value of 
sialyl-Tn in tumors and its expression at cell surface, therapeutic approaches has been 
developing cancer drugs against this epitope. Studies reported the detection of naturally 
occurring antibodies to sialyl-Tn in the serum of gastrointestinal and ovarian cancer 
patients raising the possibility of immune response towards this epitope [59]. Therefore, 
several strategies have been purposed for targeting sialyl-Tn on tumor cell surfaces in 
order to increase the production of antibodies and T cell response [48]. 
Beyond the sialyl-Tn as a major glycan of interest, the sialyl-T and disialyl-T 
antigens are commonly observed in healthy tissue, however they have been found 
overexpressed in several tumors [60]. These include testicular neoplasms [61], bladder 
tumors [9] and pancreatic adenocarcinomas [62]. The sialyl-T has been associated with 
worse prognosis and its overexpression is mediated by an increase in the expression of α2-
3 sialyltransferases, namely ST3Gal-I [63]. Another study concerning pancreatic 
carcinoma has demonstrated that sialyl-T and disialyl-T can result from a down regulation 
in core 2 β1-6-N-acetylglucosaminyltransferase, which is required for elongation of the 
mucin-type glycans [62]. 
 
4. Analytical strategies to analyze sialylated TF-related O-glycans by 
Mass Spectrometry 
Due to their biological relevance much research as focused in sialylated TF-related 
antigens. Moreover, the identification of these modifications in proteins is considered the 
first step towards understanding structure–function relationships [18]. Classical approaches 
involve mainly immunoblotting with specific antibodies and/or lectins with or without the 
combinations of enzymatic treatments to obtain structures of interest. Even though useful 
in a routine basis, structural characterization is nowadays warranted for validation of novel 
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targets. In this context, matrix-assisted laser desorption/ionization (MALDI) mass 
spectrometry (MS) has been proven a powerful, highly sensitive, tool for the structural 
analysis of complex glycans [18, 64-67].  
In MALDI, the energy of the laser is first absorbed by the matrix molecules. The 
stimulated matrix molecules transfer their excess energy to the sample molecules, which 
become ionized. For this reason, MALDI is a soft ionization method that produces 
predominantly single charges ions from the released glycans [22]. Moreover, it has the 
advantage of sample preparation and a relatively high tolerance to salts [68] and other 
contaminants, such as buffers [69]. This has enable the screen of complex mixtures for 
oligosaccharides from biological extracts, thereby revealing the type of glycans present 
[22]. However, the identification of acidic sugars, such as sialic acids, and deoxysugars, 
such as fucose, constitutes a major analytical challenge for MALDI instruments. Both 
during ionization and under typical vacuum source conditions, MALDI induces strong 
dissociation of labile glycosidic bonds in the analyzer, a process called metastable 
fragmentation [12, 70]. Derivatization strategies such as permethylation have allowed to 
stabilize this substituents overcoming the described limitation [71, 72]. However some 
drawbacks related with the formation of byproducts and the harshness of the procedure has 
strongly limited the sensitivity of this approach [20, 73]. As such, publications related with 
the analysis of permethylated sialylated O-glycans by MALDI have shown a limit of 
detection no greater than 80 picomol [74].  
4.1. Methods for the isolation of O-GalNAc glycoproteins  
Given the drawbacks associated with the analysis of sialylated TF-related glycans 
by MALDI, several enrichment methods have been introduced for O-GalNAc 
glycoproteins. The most popular enrichment techniques include the affinity 
chromatography using antibodies or lectins to selectively bind complex carbohydrate 
structures and discriminate between subtly different glycan forms [75, 76]. In addition to 
the specific lectin-affinity, approaches based on general physical and chemical properties 
glycoproteins are most valuable [77]. Among them, beads and nanoparticles are been 
functionalized with molecules with high affinity for the O-glycoproteins of interest [78-
80]. Then the purified glycoproteins are separated in a one dimension or two dimension gel 
electrophoresis [77]. After separation, proteins are transferred by electroblotting onto a 
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membrane for specific detection. The specific binding of diverse lectins to glycans can be 
used for detection and isolation of glycoproteins from human body fluids such as serum, 
and saliva [81]. It can be particularly informative to compare the “profiles” of proteins in a 
complex sample with those revealed with the specific lectin, indicating which proteins are 
glycosylated and/or aberrantly glycosylated [82, 83]. 
After enrichment/isolation of the glycoprotein of interest, O-glycans need to be 
released from the aglicone. Even though enzymes exist to remove N-glycans this is not the 
case of O-linked sugars. As there are no generic enzyme able to cleave O-glycans this is 
often achieved using chemical methods, in particular alkaline β-elimination [74]. This 
method was first suggested by Carlson et al. (1968) and is, nowadays, considered the most 
reliable for this purpose [84]. Still, this is approach is known to induce profound 
degradation of the protein moiety and peeling of the O-glycans. To reduce the degradation 
of the glycosidic domain the de-O-glycosylation is generally performed in the presence of 
sodium borohydride [85]. This reducing agent reduces the anomeric carbon (Figure 2) in 
the reducing end of the released O-glycans thus stopping further degradation [17]. Then the 
O-glycans can be isolated from other contaminants by affinity chromatography with lectins 
or antibodies [86], ion exchange [22], filtration and size-exclusion chromatography [87, 
88]. 
4.2. Analysis of sialylated glycans by permethylation 
After being released, the oligosaccharides are subjected to per-O-methylation for 
further structural analysis. Permethylation of sialic acids according Ciucanu and Kerek 
(1984) [89] method has been found most effective for analysis by MALDI MS [71, 72]. 
Permethylation of sialylated glycans has particular advantages to those underivatitized 
glycans due to (1) better ionization responses [12, 17, 18], (2) smaller mass increase and a 
greater volatility [90, 91] and (3) consequently profiled effectively using vacuum MALDI 
MS and tandem MS methods [12, 92, 93]. Although these advantages must be balanced 
against the disadvantages of the derivatization step itself. The permethylation chemistry 
has lower limit on the quantity of starting material, thereby it may be not appropriate for 
analysis available in small quantities, such as from gel spots [12, 22].   
The permethylation procedure starts with the deprotonation of the hydroxyl groups 
and other proton-donating groups in the presence of a base, such as sodium hydroxide 
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(NaOH) in anhydrous dimethyl sulfoxide (DMSO). The DMSO is a polar aprotic solvent, 
with high affinity for both native and permethylated glycans and it does not establish 
hydrogen bonds. Powdered NaOH is then introduced in the reaction media, which not only 
ensures the deprotonation of hydrogen donating groups in the glycans but also contributes 
to highly anhydrous conditions necessary for the reaction. The permethylation is then 
achieved by the introduction of a strong alkylating reagent such as methyl iodine (Figure 
2). Then, the reaction is stopped by the addiction of water and the permethylated glycans 
are extracted in chloroform or dichloromethane [12, 89, 94].  
Using optimal proportion of powdered NaOH, DMSO and methyl iodide the 
method gives high yields in one step without side products and with no special care to 
avoid exposure to air and humidity [95]. However, there are oxidative degradation and 
peeling reactions associated with the high pH resulting from dissolving NaOH powder 
prior to liquid-liquid extractions. These side reactions are adversely prominent with small 
samples (low picomole to fentomole) [21]. However, simple procedures have been found 
to improve and avoid the formation of oxidation products. The addiction of the base first 
and later methyl iodide avoids the salts formed during the interaction of DMSO and methyl 
iodide[96, 97]; the water that is used to stop the reaction can eliminate the oxidation 
products as well as neutralization of the base with a strong acid [20]. 
In attempts to introduce a semi-quantitative approach some studies report the 
introduction of internal standards such as β-ciclodextrine[18]. For a quantitative purpose 
studies reported labeling permethylation involving stable isotope label with 
13
CH3I [98, 
99]. Another development in permethylation method involves packing of sodium 
hydroxide powder in micro-spin columns or fused-silica capillaries, allowing effective 
derivatization [21]. In this approach, prior to mass spectrometry, analytes are mixed with 
methyl iodide in a dimethyl sulfoxide solution containing traces of water and infusing 
through the micro-reactors containing powdered NaOH. These solid phase permethylation 
as shown to be able to accurately and rapidly analyze picomole amounts of linear and 
branched, sialylated and neutral glycans samples. These authors further suggest that this 
type of approach reduce oxidative degradation and peeling reactions and avoid the need of 
excessive clean-up.  
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Figure 2. Reduction of oligosaccharides with sodium borohydride  and further permethylation. Adpated 
from [17]. 
 
4.3. Collision Induced Dissociation of oligosacharides  
 Accurate structural validation of O-glycans by mass spectrometry can only be fully 
achievable by tandem experiments. Collision induced dissociation (CID), is the most 
commonly used method for fragmenting oligosaccharide ions and it is used in the MALDI 
TOF/TOF equipment. Ions collide with small neutral molecules to convert the ions kinetic 
energy to vibrational energy [100]. This process involves first isolating the ion of interest, 
the precursor ion, from a mixture of ions generated during the ionization event. The ion is 
excited and collided with an inert gas such as helium, nitrogen, or argon to produce 
fragments. Kinetic energy from the collision is converted into internal vibrational energy 
that leads to bond breaking reactions [100, 101]. The process can be repeated multiple 
times depending on the mass analyzer. There are several parameters that influence the 
fragmentation behavior of oligosaccharides during the CID event. They include the 
collision energy, the amount of internal energy deposited in precursor ions upon collisions, 
the number of collisions, and the time scale between collision activation and detection. 
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CID methods can be classified in major categories based on the translational energy of the 
precursor ions, low and high energy [102].  
High energy CID results in the excitation of the electronic states in the precursor 
ion. Several types of fragmentation reactions can occur because high-energy collisions 
produce a broad internal energy distribution. MALDI TOF/TOF has been shown to 
produce high-energy collision conditions for oligosaccharides [101]. High energy collision 
conditions produce larger fractions of cross-ring cleavages such as A and X type ions [103, 
104]. However in native oligosaccharides, high energy CID often yields many peaks that 
are artifacts due to metastable dissociation. Interpreting the spectra of unknown 
compounds is therefore complicated by the presence of fake peaks [105]. 
For oligosaccharides, CID can provide sequence, branching [106], and even linkage 
[107] and stereochemistry [108, 109].Oligosaccharides that contain the same 
monosaccharides linked with a different branching structure often show distinct product 
ion patterns because the steric environments differ between such isomers and result in 
different bond energies and ion abundances in product-ion mass spectra [107]. 
The fragmentation of oligosaccharide ions is assigned according to the 
nomenclature introduced by Domon and Costello (1988) [110] (Figure 3), where product 
ions containing the reducing end of the oligosaccharide are labeled with letters from the 
end of the alphabet, X (cross-ring cleavage), Y and Z (glycosidic bond cleavage). Those 
fragments containing the non-reducing end are termed A (cross-ring cleavage), and B and 
C (glycosidic bond cleavage). Subscript numerals indicate cleavage along the glycosidic 
bond, whereas superscript numerals denote the position of the cross-ring cleavage (Figure 
3).  
 
Figure 3. The nomenclature for oligosaccharide fragmentation according Domon and Costello (1988). 
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4.4. CID of permethylated oligosaccharides 
The conversion of glycans to hydrophobic derivatives has also advantages on the 
tandem MS of permethylated oligosaccharides relative to those in native forms. When the 
permethylated glycans are subjected to CID, the glycan bond scission occurring during 
tandem MS origins “scars”. They are product ions with unique masses by virtue of the lack 
of methyl or methoxy groups, that indicate the topology and linkages for glycans [13]. On 
the other hand, tandem mass spectra of native are less structural informative, because when 
a glycosidic bond cleavage occurs, the product ion masses do not determine which bond 
was cleaved (glycosidic bond cleavages do not leave a mass “scar”) [18].  
The permethylated derivatives are often ionized as [M+Na]
+
 ions unless reversed 
phase LC/MS is used, under which conditions protonated ions ([M+H]
+
) may also be 
formed [92, 93, 107]. The fragmentation energies of the protonated ions from 
permethylated glycans are lower than the sodiated ones [111]. Therefore product ion 
patterns of protonated and sodiated forms contain different features. Thus, in the 
protonated ions from permethylated glycans produces mostly ions containing the non 
reducing end [12], while the sodiated ion fragments form abundant reducing and non-
reducing terminal product ions with approximately equal abundances [112]. Despite this 
main differences observed, both permethylated forms have in common several 
characteristics, (1) the preferential cleavage in the reducing side of HexNAc residues [91, 
113] (2) formation of a quaternary ammonium cation from the free amine groups that is 
differentiated by mass from the N-acetyl-hexosamine (HexNAc) residues [114]; and (3) the 
permethylated derivatives produces useful multiple bond fragmentation mass spectra [115]. 
This is an important advantage, because the m/z values of such ions are, in several 
situations, not distinguishable from those of primary fragments ions generated from 
underivatized oligosaccharides [17]. 
Relative to the CID spectra from the protonated permethylated glycans exhibits an 
additional ion type, the E ion. The E ion comes from eliminative losses of substituents to 
the 3-position of HexNAc that is very useful for the identification of the type of inter 
glycosidic linkage [116]. Nevertheless, in the fragmentation of protonated permethylated 
ions may undergoes by internal residue rearrangement, which difficulties the spectrum 
analysis .  
 Chapter I—17 
Taking in account the characteristics of the product ion spectra from permethylated 
glycans, the tandem MS of sialylated permethylated glycans is well established approach 
to determine overall branching structure and some structural isomers [19]. The product ion 
spectra of sialylated permethylated glycans exhibits in abundant Neu5Ac oxonium, which 
complicates the location position of substitution, because ions with glycosidic bonds to 
those residues are in low abundance [12]. Despite this,  Lemoine et al. (1991) described 
that it is possible to differentiate sialic acid linkage isomers, α2-3 and α2-6, through CID 
fragmentation, due to specific A type ions occurring to the galactose residue to which 
Neu5Ac is attached. The permethylated isomer with Neu5Acα2-6 linked produces a 
pattern in which the most abundant product ions contain the non reducing terminus and 
those that contain the reducing terminus are in low abundance. On other hand the 
permethylated isomer Neu5Acα2-3Hexose produces abundant product ion containing the 
reducing terminus [117]. The CID product ion mass spectra of sodiated permethylated 
oligosaccharides is used instead protonated ones because provide additional sensitivity to 
the linkage structure [12]. 
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O-glycosylation and aberrantly O-glycosylated proteins play a major role in tumor 
biology, biomarker research and therapeutics. The present work is within the scope of 
collaboration between Portuguese Institute of Oncology (IPO) of Porto and (Institute of 
Molecular Pathology and Immunology of the University of Porto) IPATIMUP. The 
purpose of this work was to develop an analytical approach for the analysis of trace 
amounts of sialylated TF-related antigens by MALDI TOF/TOF from low picomole of 
glycoproteins isolated by SDS-PAGE. The first part of the work is devoted to the 
establishment of the analytical bases to achieve this goal, while the second part has been 
directed towards the application the technology. Particular attention has been devoted to 
the detection of sialyl-Tn in glycoproteins from bladder and gastric cancer precursor 
lesions isolated from urine and serum, respectively. 
6. Analytical Approaches 
The sialylated TF-related antigens, namely sialyl-Tn, sialyl-T and disialyl-T, were 
analyzed by permethylation of O-glycans followed by analysis by nano-HPLC-MALDI 
TOF/TOF. Briefly glycoproteins were removed from the gel and de-O-glycosylated by 
reductive β-elimination at 45ºC for 16 hours. After the released glycan were permethylated 
based on an adaptation of the protocol described by Ciucanu and Kerek (1984) [89]. The 
permethylated O-glycans were filtred with a cutoff at 10KDa and a removal of borates was 
accomplished with 5% acetic acid in methanol. Then the resulting glycans were separated 
by nano-HPLC on a C18 reverse phase column, collected on a MALDI plate and analyzed 
by MALDI-TOF/TOF using a 2,5-dihydroxybenzoic acid (DHB) matrix [22]. A 
bioinformatics survey of the ions of interest as used to enhance the selection of the relevant 
analytical signals for MS/MS. Ion assignments were made based on the MS spectra and 
confirmed with the corresponding fragmentations by MS/MS. Spectra interpretation was 
done using the glycoworkbench platform [118]. This procedure was established using 
fetuin, a glycoprotein known to express sialylated TF-related antigens. The mentioned 
analytical platform was further applied to validate the expression of sialylated-TF antigens 
in glycoproteins from bladder and gastric cancer precursor lesions isolated from urine and 
serum, respectively. Whenever necessary, affinity chromatography methods were applied 
to recover the proteins of interest from their complex milieus.  
 Chpater III—28 
 
 
 
 
 
 
 
 
 
Chapter III. Detection of sialylated cancer-associated Thomsen-
Friedenreich - related antigens by in gel deglycosylation and 
nanoLC-MALDI-TOF/TOF   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chpater III—29 
ABSTRACT 
Malignant transformations are accompanied by an (over)expression of sialylated 
Thomsen-Friedenreich -related antigens, namely sialyl-Tn, sialyl-T and disialyl-T. These 
epitopes result from a premature stop in protein O-glycosylation and have direct impact on 
tumor biology. The proteins carrying these alterations can ultimately be shed into the blood 
stream, urine and other body fluids and thus be explored as biomarkers in non-invasive 
tests. Currently their detection relies on immuno-based methods that, even though useful in 
a routine basis, often fail to fully highlight the glycosylation pattern of a given protein. 
Herein, we have systematized a target-driven analytical approach to determine these 
glycans in minute amounts of glycoproteins (picomole) isolated from SDS-PAGE gels. 
Briefly, the proteins are to be de-O-glycosylated in gel by reductive beta elimination, 
permethylated and analyzed by nanoLC-MALDI-TOF/TOF with enhanced selection of the 
relevant analytical signals using bioinformatics tools. This has been established using 
fetuin as a model protein and used to validate the expression of sialyl-Tn in a glycoprotein 
isolated from the urine of rats with chemically-induced bladder tumors. To our knowledge, 
the presence of bladder tumor-associated sialyl-Tn antigens in urine is being reported for 
the first time and more studies are ongoing to evaluate the clinical value of this 
observation. The described approach is regarded to be of primary interest to laboratories 
equipped with nanoLC-MALDI-TOF/TOF equipments and involved in glycobiology 
research. 
 
Keywords: tumor glycosylation, mucin-type O-glycans, cancer biomarkers, Thomsen-
Friedenreich antigen, bladder cancer, MALDI 
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INTRODUCTION 
Thomsen-Friedenreich(TF)-related antigens are a class of low molecular weight O-
glycans that include the T antigen (Galβ1–3GalNAcα-O-Ser/Thr) and its precursor Tn 
(GalNAcα-O-Ser/Thr). In most human healthy tissues the T antigen is further extended and 
is often terminated by Lewis and ABO blood group antigens. Alternatively, Tn and T 
antigens can be sialylated by sialyltransferases forming sialyl-Tn (Neu5Acα2-6GalNAcα-
O-Ser/Thr), sialyl-3-T (Neu5Acα2-3Galβ1-3GalNacα-O-Ser/Thr), its positional isomer  
sialyl-6-T (Galβ1–3(NeuAcα2–6)GalNAcα-O-Ser/Thr), and disialyl-T (NeuAcα2–3Galβ1–
3(NeuAcα2–6)GalNAcα-O-Ser/Thr), thereby prematurely stopping the elongation of the 
O-glycan chain (reviewed in Reis et al. 2010) [1].  
The de novo expression of sialylated TF-related antigens is characteristic of several 
human malignancies [2]. These abnormal changes in protein glycosylation have been 
mostly attributed to a disorganization of secretory organelles and/or altered 
glycosyltransferases expression. Frequently, an increased expression of a given 
glycoprotein amplifies the alterations in secretory pathways resulting in a more 
pronounced accumulation of otherwise absent sialylated antigens. Moreover, it may 
contribute to enhancement in the basal levels of antigens already present in healthy tissues. 
In particular, sialyl-Tn has been found in breast [3], esophagus [4], colon[5], pancreas [6], 
stomach [7], endometrium [8], bladder [9], and ovary [10] carcinomas, whereas low or no 
expression is observed in the respective normal tissues [11]. The presence of this epitope 
contributes to alter cell recognition by the immune system [12], affects the adhesive 
properties of cancer cells, promotes invasion and metastasis[7, 13, 14]. As a result, it is 
being explored as a serum biomarker of poor prognosis in gastric [15, 16], colorectal [17] 
and ovarian cancer carcinomas and in tumor vaccines [18]. Sialyl-T and disialyl-T have 
also been found overexpressed in several cancers, namely testicular neoplasms [19], 
bladder tumors [20] and pancreatic adenocarcinomas [21]. Given their role in tumor 
behavior as well as biomarker and therapeutic values, much effort has been put into the 
identification of tumor-associated proteins carrying sialylated TF-related antigens. 
 The sialylated TF-related antigens have been classically determined based on 
immunoblotting [22] and more recently by in situ proximity ligation [23]. Even though 
useful in a routine basis, these methods require further characterization of the glycosylation 
pattern of a given glycoprotein. Also, validation assays using structural determination are 
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required, particularly when dealing with unknown and/or highly complex matrices. 
Moreover, at the moment there are no commercially available antibodies for mono- and 
disialylated TF-antigens. Thus the most common strategy to access these antigens is based 
on their reactivity to antibodies and lectins such as peanut agglutinin (PNA) targeting the T 
antigen, after neuraminidase treatment. As a result these sialylated glycans have been 
classified under the general designation of cryptic T antigens, which fails to provide 
information about their particular structural nature.  
 In this context, matrix-assisted laser desorption/ionization (MALDI) mass 
spectrometry (MS) has been proven a powerful, highly sensitive, tool for the structural 
analysis of complex glycans [24-28]. However, MALDI ionization induces a high degree 
of vibrational excitation in the formed ions leading to a significant dissociation of labile 
substituents [29, 30]. The analysis by mass spectrometry of sialic acid-containing glycans 
is particularly challenging, as they experience prompt fragmentation and decomposition 
[28, 31]. Permethylation overcomes this limitation by stabilizing these labile substituents 
[28], allowing their detection in positive ion mode [32]. By equalizing their chemical 
properties it also permits a semi-quantitative comparison between the permethylated 
glycans [33]. Permethylated glycans are typically observed as sodiated ions, unless 
reversed phase LC/MS is used, under such conditions protonated ions are also formed [34, 
35]. Tandem MS of permethylated glycans is also known to produce more structural detail 
than their native counterparts [36]. High energy collision induction dissociation (CID) of 
sodium ions produces mostly cross ring cleavages (A and X types; nomenclature by 
Domon and Costello 1988 [37]). In particular, the masses of specific A-type ions in Gal 
residues substituted with Neu5Ac have allowed the distinction between α2-3 and α2-6 
linkages in modern MALDI TOF/TOF instruments [38]. Conversely, protonated species 
exhibit mostly ions corresponding to the rupture of glycosidic bonds (B, C, Y types).  In 
both cases useful product ion patterns are formed, that ultimately have allowed the 
assignment of isomeric structures [39, 40]. Furthermore, the MS/MS of protonated, 
permethylated glycans does not exhibit misleading transfer products observable for native 
glycans [41]. Despite these advantages, permethylation-based analysis is conventionally 
considered not satisfactory at the range of low picomole to femtomole quantities, which are 
usually the amounts at which glycoproteins are present in biological samples [42]. This 
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limitation has hampered the use of permethylation as a viable option for the analysis of 
glycans released from SDS-PAGE gel spots.  
 Herein, we have demonstrate that a permethylation-based nanoHPLC-MALDI-
TOF-TOF approach can be used to validate and complement information from western 
blotting regarding the expression of sialylated Thomsen-Friedenreich-related antigens. 
This has been proven successful using as starting material minute amounts (low picomol 
range) of proteins isolated by SDS-PAGE.  
 
EXPERIMENTAL  
Unless otherwise stated, all reagents were purchased from Sigma-Aldrich.  
Proof of concept 
Fetuin from fetal calf serum was used as model glycoproteins in this study. 
Aliquots of 0.1 (approximately 1.6 picomol), 0.25, 0.5, 1, 1.5 µg (approximately 24 
picomol) of fetuin were electrophoresed in 4-12% Mini-PROTEAN TGX Precast Gels 
(BIORAD). Fetuin glycans were then recovered from the gel and analyzed by MALDI-
TOF/TOF as summarized in Scheme 1. Briefly, the two main bands observed after staining 
with Coomassie Brilliant Blue G-250 (Pierce-Thermo Scientific) were subsequently 
removed and subjected to in gel de-O-glycosylation. The release O-glycans were then 
permethylated and analyzed by nanoLC-MALDI-TOF/TOF with enhanced selection of the 
relevant analytical signals using bioinformatics tools (Scheme 1). Equivalent amounts of 
fetuin previously digested with neuraminidase from Clostridium perfringens were used as 
controls. After validation, the analytical approach presented in Scheme 1 was applied to 
the analysis of bladder tumor associated urinary glycoproteins. Preliminary studies were 
also performed to determine the limit of detection of MALDI-TOF/TOF for permethylated 
O-glycans released by chemical de-glycosylation from native fetuin and purified by 
filtration.  These studies included fetuin amounts between 50 ng (approximately 0.8 
picomol) and 1.5 µg (approximately 24 picomol. All experiments were done in triplicates.  
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Scheme 1. Overview on the analytical approach developed for the analysis of trace 
amounts of sialylated TF-related glycans. 
 
Animal model 
 Twenty female Wistar rats were obtained at the age of 5 weeks from Harlan 
(Amsterdam, Netherlands). The rats were used in this study after a week of 
acclimatization. During the experimental protocol, animals were housed in collective 
plastic cages with ad libitum access to food and water. The room temperature and the 
relative humidity were controlled at 22±2ºC and 60±10%, respectively. Fluorescent 
lighting was provided in a 12-h light/dark cycle. The animals were randomly divided into 
two groups: control group (n=10 rats) and urothelial carcinogenesis group induced by 
exposure to N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN; n=10 rats) described by 
SDS-PAGE 
In gel de-O-glycosylation 
(NaOH 50 mM; NaBH4 1M) 
Permethylation (DMSO; 
NaOH; CH3I) 
Filtration 10KDa filters 
Removal of borates (5% 
acetic acid in methanol) 
Nano-HPLC 
MALDI TOF-TOF 
Bioinformatics survey 
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Oliveira et al. (2007) [43]. All procedures were performed in accordance with the 
European Communities Council Directive 2010/63/EU . 
Induction and characterization of BBN-resulting urothelial carcinogenesis 
In order to induce urothelial carcinogenesis, one group of animals (BBN; Tokyo 
Kasei Kogyo) was treated with BBN. The BBN was administered in the drinking water, in 
light impermeable bottles, at a concentration of 0.05%. Control animals served as the 
control without any chemical supplementation in drinking water. The animals were 
observed daily for health check. The urothelial carcinogenesis group was exposed to BBN 
for 20 weeks and was maintained with normal tap water until the end of the experiment. 
After 28 weeks, the animals from control group and urothelial carcinogenesis group were 
both were sacrificed with 0.4% sodium pentobarbital (1 ml/Kg, intraperitoneal) and 
gastrocnemius muscle was dissected out. Complete necropsies were carefully conducted. 
All organs were examined macroscopically for any changes. The urinary bladders were 
inflated in situ by injection of 10% phosphate-buffered formalin (300 µl), ligated around 
the neck to maintain proper distension and then were immersed in the same solution for 12 
h. After fixation, the formalin was removed; the urinary bladder was weighed and cut into 
two parts and was routinely processed for haematoxylin and eosin staining. 
Immunohistochemistry 
Formalin-fixed paraffin embedded (FFPE) urothelium sections from controls and 
animals with BBN-induced urothelial carcinomas were screened for sialyl-Tn by 
immunohistochemistry using the avidin/biotin peroxidase method. Briefly, 2 m sections 
were deparaffinised and hydrated with xylene and graded ethanol series, and exposed to 
3% hydrogen peroxide in methanol for 20 minutes, to reduce endogenous peroxidase 
activity. No antigen retrieval steps were necessary to determine this particular epitope. The 
expression of sialyl-Tn was then evaluated using anti-sialyl-Tn mouse monoclonal 
antibody TKH2. The sections were first blocked with BSA (5% in PBS) for 30 minutes to 
avoid non-specific and then incubated with TKH2 at room temperature for 30 min. 
Afterwards the sections were washed with PBS-T and incubated at room temperature for 
30 minutes with the Vectastain Elite ABC peroxidase kit (Vector Lab).  After washing in 
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PBS-T, the sections were incubated with 3,3-diaminobenzidine tetrahydrochloride (DAB, 
Dako) for 5 minutes at room temperature to visualize antibody binding sites. Finally, they 
were counterstained with hematoxylin for 1 minute. Positive and negative control sections 
of intestinal metaplasias were tested in parallel. The negative control sections were 
performed by adding BSA (5% in PBS) devoid of any antibody. The expression of this 
epitope was evaluated by microscopic screening of sections exhibiting a maximum of 
negative and positive stained cells.  
Urine collection and isolation of urine glycoproteins 
The urines from control group and urothelial carcinogenesis group were collected 
for 24 hours using metabolic cages. The urines were then centrifuged at 8,000 g at room 
temperature for 15 min to remove cells and debris and conserved at -80ºC. No special 
treatment was performed to remove occasional microhematuria, in order to preserve the 
intrinsic components of the sample. After thawing, each sample was dialyzed with 
Spectra/Por MWCO 12-14 (Spectrum Laboratories) against dionized water, lyophilized, 
redissolved in 5% SDS, dialyzed again against 1.5% SDS at 60ºC and finally dionized 
water as described by Halim et al. (2012) [44]. The protein content in each sample was 
determined colorimetry using the RC-DC protein quantification kit (BIORAD). Pools of 
equal amounts of protein (40 µg) were then constructed for the controls and sialyl-Tn 
positive tumors using the urine of 3 animals.   
Western blotting 
 Equivalent amounts urinary proteins (20 µg) were separated by gel electrophoresis 
(12% Mini-PROTEAN TGX Precast Gels (BIORAD)), which were prepared in duplicate 
for each experiment. The proteins from one of the gels were blotted on a nitrocellulose 
membrane (Hybond-ECL; Amersham Pharmacia Biotech), and the other gel was stained 
with Colloidal Coomassie Blue for protein visualization. To verify an equal amount of 
sample loaded, membranes containing transferred proteins were reversibly stained with 
Ponceau S. Nonspecific binding to the membrane was blocked with 1% carbo-free 
blocking solution (v/v) (Vector Laboratories). Sialyl-Tn was determined with mouse 
monoclonal antibody TKH2. Incubation was carried out at 4ºC for 16 hours. Next, 
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membranes were washed with TBS-T (TBS with 0.5 % Tween 20), incubated with 
secondary horseradish peroxidase-conjugated anti-mouse or anti-rabbit (GE Healthcare) 
for 30 min, and washed again with TBS-T. Reactive bands were detected by enhanced 
chemiluminescence ECL plus (Amersham Pharmacia Biotech) according to the 
manufacturer's procedure. Images were recorded using X-ray films (Kodak Biomax light 
Film, Sigma). The films were scanned in Molecular Imager Gel Doc XR+ System (Bio-
Rad) and analyzed with QuantityOne software (v 4.6.3 Bio-Rad).  Bovine fetuin and 
albumin were used as positive and negative controls, respectively.  
In gel O-deglycosylation and permethylation 
 The bands of interest were removed from SDS-PAGE gels and de-O-glycosylated 
by reductive β-elimination upon incubation with 50 mM NaOH and 1M NaBH4 at 45ºC for 
16 hours.  The reaction was stopped with glacial acetic acid until no fizzing was observed 
and the samples were subsequently filtered using 10 kDa molecular weight cutoff 
(MWCO) (Millipore). The filtrated containing low molecular weight peptides, O-glycans 
and borate salts was recovered and incubated several times with methanol containing 5% 
(v/v) acetic acid under a stream of nitrogen to remove borates as methyl esters.  
 The O-glycans were then permethylated adopting a modification of the method by 
Ciucanu and kerek 1988 [45]. Briefly, the native O-glycans were dissolved in 100 µL of 
DMSO, and powdered NaOH containing trace amounts of water was added to the reaction 
medium. The mixture was sonicated for 30 min and frozen prior to the addition of 10 µL of 
CH3I and then incubated under mild stirring for 1 h. The permethylated oligosaccharide 
were recovered from the reaction mixture by extraction with dichloromethane and 
extensively washed with acidified water (pH 2.0) to avoid base-induced hydrolysis of 
permethylated sialic acids. The samples were then de-salted using Dowex ion-exchange 
resin (Dowex 50W-X8; biorad).  
Nano-HPLC- MALDI-TOF/TOF 
 The permethylated O-glycans were separated in a nano-HPLC Ultimate 3000 
system (Dionex, Amsterdam) equipped with a capillary column (Pepmap100 C18; 3 μm 
particle size, 0.75 μm internal diameter, 15 cm in length). The samples were dissolved in 
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5% acetonitrile (ACN) aqueous solution containing 0.1% trifluoroacetic acid (phase A). 
The separation was performed using a linear gradient of 32-50 % B for 45 minutes, 50-70 
% B for 10 minutes and 70-32% A for 5 minutes. The eluted glycans were applied directly 
on a MALDI plate in 10 seconds fractions using an automatic fraction collector Probot 
(Dionex, Amsterdam) under a continuous flow rate of 270nL of 2,5-dihydroxybenzoic acid 
(DHB matrix solution (10 mg/mL in 70% acetonitrile/0.1% TFA and internal standard 
Glu-Fib at 15ftmol). Mass spectra were obtained on a matrix assisted laser 
desorption/ionization–time of flight MALDI TOF/TOF mass spectrometer (4800 
Proteomics Analyzer, AB SCIEX, Foster City, CA, USA) in the positive ion reflector 
mode and obtained in the mass range from 600-4500 Da with 1200 laser shots. For the 
experiment, Glu-Fib was used for internal calibrations. A data dependent acquisition 
method was created to select the 16 most intense peaks in each sample spot for subsequent 
tandem mass spectrometry (MS/MS) data acquisition. The MALDI-MS data from each 
chromatographic run was combined into a three dimensional data array (fraction number, 
m/z, ion current). A survey of plausible analytical signals at m/z 669.38, 691.36, 873.48, 
895.46, 1234.65 and 1256.64 was performed by determining the most prominent peaks 
occurring within 0.2 and 0.5 Da of the reference peak. Visual analysis of the distribution of 
the identified signals allowed the identification of chromatographic envelops. The 
subsequent MS/MS analysis was governed by the results of this data mining technique and 
was able to successfully identify the targeted structures. Peak assignments in MS and 
MS/MS spectra and database searches were performed using the GlycoWorkBench 
platform [46]. 
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RESULTS AND DISCUSSION   
The presence of sialylated TF-related antigens in glycoproteins has been 
conventionally determined by immunoblotting using antibodies and lectins; still structural 
characterization is nowadays warranted for validation.  
The detection of sialylated glycans by MALDI poses a major analytical challenge 
due to the significant degree of dissociation of sialic acids under this type of ionization, in 
particular in the reflector mode [36, 47]. Even though the instruction of permethylation has 
overcome this limitation by the high pH used in the reaction induces a significant degree of 
oxidative degradation and peeling reactions. Undesirable by-products are also promoted by 
the high pH, reductive environment and the temperature necessary for the de-O-
glycosylation of proteins in the absence of specific O-glycosidases. This synergism of 
factors is responsible by the introduction of significant background noise and, in some 
extent, the degradation of the glycans under analysis. As a result, doubts persist about the 
efficiency of combined approach based upon chemical de-O-glycosylation and 
permethylation to determined glycosylation patterns from low picomole to femtomole 
quantities of proteins isolated by SDS-PAGE. This work is now focused on the 
demonstration that in-gel de-O-glycosylation and permethylation coupled with nanoLC-
MALDI-TOF/TOF and comprehensive bioinformatics (summarize in Scheme 1) can allow 
the detection of low picomole of sialylated T-related antigens. 
 
 Determination of sialylated TF-related antigens in fetuin by MALDI 
Fetuin, recognized to yield the two isomeric forms of sialyl-T (s3T and s6T) [48, 
49], disialyl-T [50] and, in less extent, sialyl-Tn, was elected as a model glycoprotein for 
proof of concept. Preliminary studies were performed to determine the limit of detection of 
MALDI-TOF/TOF for permethylated O-glycans released by chemical de-glycosylation 
from native fetuin and purified by filtration. This allowed the detection of ions consistent 
with O-glycans from fetuin amounts as low as 0.1 µg (approximately 1.6 picomol). Based 
on these observations, amounts of fetuin ranging from 1.6 to 24 picomol were separated in 
SDS-PAGE and stained with Colloidal Coomassie Blue thereafter. The two main bands 
observed between 50 and 75 kDa (Figure 1a) were then recovered and subjected to in-gel 
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de-O-deglycosylated by reductive β-elimination. The resulting glycans were isolated by 
filtration and permethylated in a non-anhydrous environment, as described by Ciucanu and 
Kerek (1984) [45], to enhance reactions yields and minimize undesirable reactions. The 
glycans permethylated in this way were further analyzed by MALDI-TOF resulting in MS
 
spectra similar to the one presented in Figure 1b for 4 picomol of fetuin. In accordance 
with previous reports [48, 49, 51], we have identified several sodium and oxonium ions 
consistent with O-glycans exhibiting a core 2 backbone (Galβ1-3(Galβ1-4GlcNAcβ1-
6)GalNAcα1-Ser/Thr). These assignments have been comprehensively resumed in Table 1 
and Figure 1b and include several O-glycans that have not been previously described.  Ions 
belonging to complex type N-glycans were also detected (Table 1, Figure 1b), most likely 
as consequence of the non-specific nature of the deglycosylation protocol. However, 
sialylated TF-related glycans could not be accurately distinguished from background noise 
under the used conditions (Figure 1c).  
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Figure 1. a) Electrophoretic profile of fetuin in 4-12% SDS-PAGE highlighting the amount of glycoprotein 
used for in gel de-O-glycosylation, b) Positive MALDI-MS spectra of permethylated O-glycans released 
from 4 picomol of fetuin with an expansion highlighting the ions assigned in Table 1, and c) expansion of the 
zones of the spectrum were sialyl-Tn, sialyl-T (s-3-T and s-6-T) and disialyl-T ions are expected.  (  - Fuc; 
 - Man;  - Gal;  - GalNAc;  -  GlcNAc; - Neu5Ac) 
 
 
 
 
 
 
a) 
b) 
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Table 1. Permethylated glycans generated by chemical de-O-glycosylation of 4 picomol of fetuin showing 
MALDI-MS ions with a signal-to-noise ratio superior to 10. (  - Man;  - Gal;  - GalNAc;  -  
GlcNAc; - Neu5Ac) 
 
 
ion (m/z) 
 
Ion 
type 
Glycosidic 
family 
Assigned structure Reference 
 
O-glycans 
    
     
669.4/691.4* H
+
/Na
+
 Core 1 
 
[50] 
757.4/779.4 H
+
/Na
+
 Core 2 
 
[51] 
873.5/895.5 H
+
/Na
+
 Core 2 
and/or        
[48, 49, 
51] 
 
983.5 
Na
+
 Core 2 
 
[49, 51] 
1024.5 Na
+
 Core 2 GlcNAc2Gal1GalNAcol NR 
1176.6 H
+
 Core 2 GalNAc1GlcNAc1Gal1GalNAcol NR 
1228.6 Na
+
 
Core2/Core 
1 
GlcNAc2Gal2GalNAcol NR 
1234.7/1256.6 Na
+
 Core 2 
 
[48, 49, 
51] 
1350.7 H
+
 Core 2 Fuc2GlcNAc2Gal1GalNAcol NR 
1380.7 H
+
 Core 2 Fuc1GlcNAc2Gal2GalNAcol NR 
1385.7 Na
+
 Core 4 Neu5Ac1Gal1GlcNAc2GalNAcol NR 
1402.7 H
+
 Core 2 Fuc1GlcNAc2Gal1GalNAcol NR 
1479.8 H
+
 Core 2 Neu5Ac2Gal1GlcNAc1GalNAcol NR 
1535.8 Na
+
 Core 2 Fuc2GlcNAc1Gal3GalNAcol NR 
1576.8 Na
+
 Core 2 Fuc2GlcNAc2Gal2GalNAcol NR 
1606.8 Na
+
 Core 2 Fuc1GlcNAc2Gal3GalNAcol NR 
1683.9 H
+
 Core 2 
 
[48, 49, 
51] 
1933.0 H
+
 Core 2 Fuc3GlcNAc2Gal3GalNAcol NR 
1987.0 H
+
 Core 2 Neu5Ac1Gal2GalNAc2GalNAcol NR 
2133.1 H
+
 Core 2 Neu5Ac2Gal3GlcNAc2GalNAcol NR 
2307.2 H
+
 Core 2 Neu5Ac2Fuc1Gal3GlcNAc2GalNAcol NR 
2569.3 H
+
 Core 2 Neu5Ac1Fuc2Gal4GlcNAc3GalNAcol NR 
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N-glycans 
2425.3 H
+
 
complex 
type 
 
[52] 
2786.4 H
+
 
complex 
type 
Neu5Ac2Gal2GlcNAc3Man3GlcNAcol [52] 
2896.5 Na
+
 
complex 
type 
 
[52] 
 
* - Traces  
NR - non-reported  
 
 
In an attempt to enhance the signals of interest, the permethylated glycans were 
then separated by nano-HPLC using a C18 reverse phase column prior to analysis by 
MALDI. The MALDI-MS data from each chromatographic run was combined into a three 
dimensional data array (Fraction Number vs m/z vs nano-HPLC-MALDI-MS signal) and 
the distribution of the signals within 0.5 Da of the ions of interest were comprehensively 
analyzed. The surveyed ions include both protonated and sodiated forms of sialyl-Tn (m/z 
669.4 and 691.4), sialyl-T (m/z 873.5 and 895.7) and disialyl-T (m/z 1234.7 and 1256.6). 
All the above mentioned ions exhibited sparse matrix plots with clusters of high-intensity 
signals similar to those presented in Figure 2a and b for sialyl-T. These patterns showed a 
lesser dispersion of m/z values over particular regions consistent with chromatographic 
envelopes (Figure 2a and 2b), strongly suggesting the presence of the targeted compounds. 
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Figure 2. Plots of the sparse matrix (Fraction Number vs m/z vs nano-HPLC-MALDI-MS signal) for the 
peaks found within  873.5±0.5 Da (a and c) and 895.5±0.5Da (b and d), which includes the monoisotopic 
mass of protonated and sodiated forms of sialyl-T, respectively. Plots a) and b) refer to O-glycans resulting 
from 4 picomol of native fetuin, whereas c) and d) refer to fetuin subjected to treatment with an α-
neuraminidase. A chromatographic envelop is visually detected in figures a) and b) both due to the existence 
of a cluster of high-intensity signals, but also by the lesser dispersion of m/z over the envelope region. 
 
Noteworthy, despite the exposure of the permethylated glycans to a cation-
exchange resin prior to analysis and the use of acidified solvents for the chromatographic 
run, both protonated and sodiated ions were detected. The presence of sodiated and 
protonated forms most likely results from differences in the coordination of the proton and 
the sodium cation with the oxygens of the permethylated carbohydrates. According to 
Cancilla et al. (1996) [53] the protonation occurs via the oxygen of the glycosidic bond, 
whereas the sodium ion establishes a more stable binding with multiple oxygen atoms.  
Based on the generated plots it was possible to accurately identify LC fractions like the 
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ones presented in Figure 3, showing distinguishable signals for both protonated and 
sodiated ions. However, the chromatographic envelopes were only present in the assays 
concerning fetuin contents higher than 1.6 picomol. For amounts of fetuin bellow this 
range, the poor quality of the spectra did not allow to undoubtedly assign ions associated 
with permethylated O-glycans. 
 
 
 
Figure 3. Nano-HPLC-MALDI-MS fractions exhibiting distinguishable signals for a) sialyl-Tn, b) sialyl-T 
(s-3-T and s-6-T ), and c) disialyl-T [M+H]
+
 and [M+Na]
+
 ions. (  - Gal;  - GalNAc; - Neu5Ac)   
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 Moreover, fluctuations that can go up to 20 ppm in relation to the expected 
monoisotopic masses were observed for a given ion within a chromatographic run. These 
deviations are most likely a consequence of lack of homogeneity in the crystallization of 
the matrix and changes in solvent composition during chromatography. To ensure the 
accuracy of the above assignments the glycans were digested with α-neuraminidase prior 
to permethylation. Such resulted in the loss of the chromatographic envelope for all ions 
and conditions tested (Figure 2c and d), thus confirming the existence of sialic acids. The 
subsequent MS
2
 analyses, necessary to achieve inequivocous structural assignments, were 
governed by the results from the above described data mining technique. Namely, we 
selected LC fractions exhibiting proton and/or sodium adducts of sialyl-Tn, mono and di-
sialyl-T with signal-to-noise ratios higher than 50 for MS
2
 experiments. The characteristic 
product ion spectra for protonated and sodiated ions of the species under study have been 
summarized in Figure 4 and 5, respectively. They showed that, irrespectively of the type of 
adduct, there is a predominance of  ions resulting from combination of X type cross-ring 
fragmentations with one or several B, C, Y and Z type fragmentations (nomenclature 
fragmentation according to Domon and Costello (1988) [37]). This array of fragmentations 
occurs at both the reducing and non-reducing terminals and results from the high degree of 
energy induced by CID and vacuum conditions [54, 55]. Despite these constrains, all 
shown spectra presented fragmentation patterns consistent with the ions under study.  Of 
note, the product ion spectra of the protonated form of sialyl-T (Figure 4b), exhibits the 
ions at m/z 364.2, 408.2 and 713.4 resulting from combined fragmentations of Gal and 
sialic acids linked to a GalNAc residue, thus characteristic of s-6-T. However, no specific 
reporter ions have been found for s-3-T that has also been described in fetuin. Conversely, 
the sodiated counterpart (Figure 5) exhibits a low intensity ion at m/z 477.2 and another at 
m/z 733.3 consistent with sialic acids linked to Gal residues only present in the s-3-T 
isomer. No signals attributable solely to s-6-T could be found. These observations suggest 
that a careful evaluation of both protonated and sodiated adducts should be undertaken to 
achieve full structural assignments. 
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Figure 4. MALDI-TOF/TOF CID spectra of [M+H]+  permethylated a) sialyl-Tn, b) sialyl-6-T, and c) 
disialyl-T exhibiting characteristic fragmentations according to the nomenclature introduced by Domon and 
Costello (1988) [37]. “*” signals resulting from the combination of cross-ring and glycosidic bound 
fragmentations occurring at both the reducing and non-reducing ends. (  - Gal;  - GalNAc; - 
Neu5Ac) 
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Figure 5. MALDI-TOF/TOF CID spectra of [M+Na]+  permethylated a) sialyl-Tn, b) sialyl-T, and c) 
disialyl-T exhibiting characteristic fragmentations according to the nomenclature introduced by Domon and 
Costello (1988) [37]. “*” signals resulting from the combination of cross-ring and glycosidic bound 
fragmentations occurring at both the reducing and non-reducing ends. (  - Gal;  - GalNAc; - 
Neu5Ac) 
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In summary, it has been demonstrated that an hyphenated approach using  in-gel 
de-O-glycosylation, permethylation and nano-HPLC-MALDI-TOF/TOF backed by 
comprehensive bioinformatics allows the detection of sialylated TF-related antigens from 
low picomole to femtomole amounts of a glycoprotein of interest. Noteworthy, this 
technique also enabled the assignment of low molecular weight glycans found in zones of 
the spectra with strong background noise generated by acidic matrices such as DHB [56]. 
This was the case of the sialyl-Tn whose analysis by MALDI is being described, to our 
knowledge, for the first time. It should however be pointed out that, in those cases, a prior 
knowledge of the ions of interest is necessary, making this a target-driven approach.  
  
 Determination of sialylated TF-related antigens in bladder-cancer associated 
glycoproteins  
Despite the biological importance of sialyl-Tn in human malignancies [2, 13] and 
the ongoing efforts to develop cancer vaccines using this epitope [57], scarce information 
has been provided regarding its role in bladder tumors. Within the scope of our current 
research on this topic, we have performed immunohistochemistry staining against sialyl-Tn 
on serial FFPE rat urothelium sections exhibiting no-tumors and chemically-induced 
tumors. These studies showed no reactivity between the anti-sialyl Tn monoclonal 
antibody TKH2 and the healthy urothelium, demonstrating that this glycan is not 
expressed.  Conversely, several tumors exhibited membrane and, to some extent 
cytoplasmatic immunostaining, consistent with the sialyl-Tn expression pattern [58, 59] 
(Figure 6a). We have further hypothesized that the glycoproteins carrying this modification 
are likely to be shed into the urine. Based on these observations, we have collected the 
urines of healthy rats and also those presenting sialyl-Tn positive tumors. The proteins on 
these urines were further purified by dialysis, combined in two pools (healthy and bladder 
tumor) of equal amounts, separated by SDS-PAGE, stained with Colloidal Coomassie Blue 
and blotted for sialyl-Tn. This highlighted a band at 25 kDa that was solely observable in 
the sialyl-Tn positive bladder tumors associated urines (Figure 6b). Moreover, this band 
showed considerable cross-reactivity to TKH2 antibody strongly suggesting the presence 
of sialyl-Tn (Figure 6b). The amount of material in this band obtained by comparing the 
intensities of staining with bovine serum albumin standards applied in the same gel was 
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roughly estimated to be 60 picomol (1.5 µg). As described for fetuin, the band of interest 
was further isolated, the glycans released by chemically-assisted de-O-glycosylation, 
permethylated and analyzed by nano-HPLC-MALDI-TOF/TOF. Likewise, negative 
controls consisting of de-sialylated glycoprotein have also been analyzed. As shown by the 
plots in Figure 3c and d, the tumor-associated urinary glycoprotein exhibited a 
chromatographic envelope over the m/z values of both protonated and sialylated forms of 
sialyl-Tn (Figure 6c), that disappeared after treatment with the α-neuraminidase (Figure 3a 
and c). These assignments were further validated by MS
2
 (spectrum similar to the one 
presented in Figure 4a) thus confirming blotting observations. This constitutes the first 
description of sialyl-Tn in urine in the context of bladder cancer. Studies are ongoing to 
determine the identity of the glycoproteins carrying this abnormal posttranslational 
modification and validate the association with bladder cancer. Noteworthy, nothing is 
known about the patterns of sialyl-Tn in human bladder tumors and its clinical value. 
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Figure 6.  a) Rat urothelium with BBN-induced tumor showing intense immunostaining 
for sialyl-Tn; b) SDS-PAGE gel section from urine proteins showing a tumor-specific band 
at 25 kDa (I) immunoreactive with anti-sialyl Tn monoclonal antibody TKH2 (II); c)  Plots 
of the sparse matrix (Fraction Number vs m/z vs nano-HPLC-MALDI-MS signal) for the 
peaks found within  669.4±0.2 Da, which includes the monoisotopic mass of protonated 
form of sialyl-Tn. 
 
CONCLUSIONS 
 The assignment of sialylated TF-related antigens by MALDI poses a major 
analytical constrains that have been partially overcome by permethylation of the native 
glycans. Still, this derivatization is far from being a straightforward approach as often 
produces several undesirable byproducts. As a result it has been mostly applied when 
considerable amounts of glycoproteins are available. Only one study has suggested its 
application within the picomole range, yet no attempts have been made to analyze glycans 
expressed in low abundance and isolated from gel spots [60]. Our study has now 
Control          tumor
25 kDa
I
II
a)
b)
c)
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demonstrated that this technique can be scaled down to glycoprotein amounts higher than 
1.6 picomol based on hyphenated approach involving permethylation and nano-HPLC-
MALDI-TOF/TOF backed by comprehensive bioinformatics. Moreover, it has been 
applied successfully to glycoproteins isolated in gel spots which has been regarded as one 
of the main limitations of permethylation.  This analytical approach will allow the 
validation of immune-based assignments from low amounts of starting material and, as 
such, of great interest those working in the field of glycobiology and proteomics.  
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ABSTRACT 
Gastric cancer is a global health burden and the second cause of cancer related 
mortality worldwide. It is generally associated to the development of gastritis, that can lead 
to chronic atrophic gastritis, and intestinal metaplasia which are regarded as percursors of 
gastric adenocarcinoma. Currently, the diagnostic for these primary lesions relies almost 
exclusively in endoscopy followed by biopsy, which is both invasive and costly to apply in 
a routine basis. Therefore, biomarkers which can assist the non invasive screening for 
silent gastric pathologies are highly needed. In this context, our current glycoproteomic-
based studies by western blot have shown an association between serum plasminogen 
carrying the tumor-associated carbohydrate sialyl-Tn antigen and the above mentioned 
percursor stages.  
To confirm these findings, plasminogen was enriched from serum of patients with 
gastritis and intestinal metaplasia by lysine-sepharose affinity chromatography and further 
isolated by gel electrophoresis. The presence of sialyl-Tn was then accessed by nanoLC-
MALDI-TOF/TOF using the methodology described in chapter III of this dissertation. This 
approach allowed the validation of western blot assignments thereby setting the structural 
basis for a novel biomarker for the early detection of gastric cancer.   
 
 
Keywords: sialylated TF-related antigens, gastritis, intestinal metaplasia, sialyl-Tn, 
plasminogen, permethylation 
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INTRODUCTION  
Gastric cancer is a global health burden and the second cause of cancer related 
mortality worldwide. The development of gastric cancer is associated with a long 
carcinogenesis pathway generally initiated by the Gram-negative bacterium Helicobacter 
pylori [2]. Infection may result in the development of gastritis, that can lead to chronic 
atrophic gastritis, and intestinal metaplasia which are regarded as precursors of gastric 
adenocarcinoma [3]. Currently, the diagnostic for these precursor lesions relies almost 
exclusively in endoscopy followed by biopsy, which is both invasive and costly to apply in 
a routine basis [4]. Therefore, biomarkers which can assist the non invasive screening for 
silent gastric pathologies are highly needed.  
Glycosylation is a common post-translational modification of proteins with more 
than half of eukaryotic proteins thought to be glycosylated [5]. The pattern of protein 
glycosylation is cell and tissue specific  and closely reflects the physiological status of the 
cell [6]. Thus, changes in glycan expression are being observed for several pathological 
conditions and in particular in gastric lesions [7]. Those include the aberrant expression of 
simple mucin type carbohydrate antigens, namely T (Galβ1–3GalNAcα-O-Ser/Thr), Tn 
(GalNAcα-O-Ser/Thr), and sialyl-Tn (Neu5Acalpha2-6GalNAcα-O-Ser/Thr) [8-11]. An 
overexpression of sialylated Lewis antigens [12] and the decreased expression of terminal 
αGlcNAc O-glycans [10, 13, 14] has also been reported. As a result, some of the most 
promising biomarkers for arise from alterations in the glycosylation pathways 
accompanying oncogenic transformations. Protein carrying these alterations can ultimately 
be released into the blood stream and constitute a valuable biomarkers [15]. Indeed, the 
majority of the serological cancer biomarkers known to date are either glycans at cell 
surface of the tumor (attached to glycoproteins or glycolipids) or in secreted glycoproteins. 
Among the most proheminent serological assays are the ones targeting carbohydrate 
antigens sialyl Lewis a (CA19-9) and sialyl-Tn (CA72-4) or mucin glycoproteins such as 
MUC1 (CA15-3) and MUC16 (CA125) [7]. 
In this context, our current glycoproteomic-based studies by western blot have 
shown an association between serum plasminogen carrying the tumor associated 
carbohydrate sialyl-Tn (Neu5Acα2-6GalNAc-O-Ser/Thr) antigen gastric cancer precursor 
lesions. In line with these observations sialyl-Tn has been previously observed in pre-
malignant lesions of the gastrointestinal tract, namely in intestinal metaplasia [16]. 
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Acknowledging the biomarker value of these observations, the present work is devoted to 
the validate the western blot assignments. 
As such, we have isolated plasminogen from serum samples associated with 
gastritis and the two types of intestinal metaplasia (complete and incomplete). Using the 
analytical approach described in chapter III it was possible to detect by MALDI-TOF/TOF 
sialyl-Tn in the plasminogen associated with gastric pathologies, thus validating western 
blot data. 
 
EXPERIMENTAL METHODS 
Serum collection and enrichment of Plasminogen  
The plasminogen was isolated from serum of several patients with gastritis, 
intestinal metaplasia (complete and incomplete) as well as healthy donors using lysine 
sepharose affinity chromatography as described by Deutsch, and Mertz (1970) [17].The 
beads of lysine sepharose (200µL) were washed 5 times with 2-3 bed volumes of binding 
buffer (phosphate 50mM; pH 7.5) and incubated with 150µL serum and 400µL of  binding 
buffer overnight to a 4ºC. In the next day the beads were washed 5 times with binding 
buffer and eluted with 200µL elution buffer (phosphate 50mM; pH 7.5, 0.2M of 
aminocaproic acid) 3 times. The protein content in each sample was determined using RC-
DC protein quantification Kit (BioRAD). The recovered proteins were then separated by 
SDS-PAGE (9% Mini-PROTEAN TGX Precast Gels (BIORAD)) and stained with 
Coomassie Blue. The plasminogen bands were removed from SDS-PAGE gels and the 
protein identity was confirmed by MALDI MS. Equivalent amounts of plasminogen 
previously digested with neuraminidase from Clostridium perfringens (Sigma-Aldrich; 
Karlsruhe, Germany) were used as a control. 
Protein selection and in-gel tryptic digestion. 
One dimension gels were stained with Coomassie Blue (Bio-Safe Coomassie from 
Bio-Rad, CA) overnight and images were acquired with a Gel Doc XR system (Bio-Rad, 
CA). The spots corresponding to plasminogen were removed from the gel, destained, and 
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submitted to in-gel tryptic digestion and the peptides extracted according to the trypsin’s 
manufacturer instructions (Promega, USA). 
Protein identification by MALDI-TOF/TOF 
The tryptic digests were separated with a C18 Pepmap (Dionex) column on an 
Ultimate 3000 (Dionex/LC Packings, Sunnyvale, CA) nano-HPLC and fractions were 
collected with a Probot (Dionex/LC Packings, Sunnyvale, CA) directly onto a matrix 
assisted laser desorption ionization (MALDI) plate. The MALDI-TOF/TOF (time-of-
flight) mass spectrometry (MS) analysis was performed on a 4800 MALDI-TOF/TOF 
Analyzer (Applied Biosystems, Foster City, CA). The MS and MS/MS spectra acquired 
were processed and analyzed by the Global Protein Server Workstation (Applied 
Biosystems). Protein identification was achieved with a search performed against the 
Swiss-Prot protein database (March 2009, 428 650 entries) for Homo sapiens using the 
Mascot search engine (Version 2.1.04, Matrix Science, UK). The search included peaks 
with a signal-to-noise ratio greater than 10 and allowed for up to two missed trypsin 
cleavage sites. To be considered a match a confidence interval, calculated by the AB 
SCIEX GPS Explorer software, of at least 99% was required.  
 
In gel de-O-glycosylation and permethylation and nanoLC-MALDI-TOF/TOF 
 
The band corresponding to plasminogen was removed from SDS-PAGE gels and 
screened for sialyl-Tn by in-gel de-O-glycosylation, permethylation and nanoLC-MALDI-
TOF/TOF using the methodology described in chapter III.  
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RESULTS AND DISCUSSION 
Western blot screening for tumor-associated simple mucin type O-glycans in serum 
proteins as resulted in the identification of plasminogen carrying sialyl-Tn. Of particular 
interest, these abnormal O-glycosylated form of plasminogen has been mostly observed in 
gastritis and, in particular, intestinal metaplasia (complete and incomplete). Moreover, no 
expression was found among healthy individuals, reinforcing the putative value of this 
observation in the early detection of gastric cancer precursor lesions. To confirm blot-
based assignment we have isolated plasminogen from serum samples associated with 
gastritis and the two types of intestinal metaplasia (complete and incomplete) as well as 
healthy donors. The presence of sialyl-Tn was then accessed using the analytical approach 
developed in chapter III comprising in gel reductive β-elimination, permethylation and 
nanoLC-MALDI-TOF/TOF. 
The glycoprotein of interest was primarily enriched with lysine-sepharose from 
serum of patients with gastritis and intestinal metaplasia as well as from healthy donors. 
The lysine-sepharose is a resin with its amino and carboxyl groups free to interact with the 
negative charges of glutamic acid residues as well as Neu5Ac presents on plasminogen. 
The samples enriched in plasminogen were then separated in a gel electrophoresis SDS-
PAGE 9% (Figure 1a). Then the spots at 100 kDa corresponding to plasminogen, as 
confirmed by protein identification by MALDI-TOF/TOF, were recovered from the gel 
and subjected to in-gel de-O-glycosylation by reductive β-elimination (Figure 1a). The 
resulting oligosaccharides were filtered for further permethylation with traces of water, 
according to Ciucanu and Kerek (1984) [18]. The permethylated glycans were separated by 
nano-HPLC using a C18 reverse phase column and analyzed by positive mode  MALDI-
TOF/TOF. 
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Figure 1. a) SDS-PAGE gel showing plasminogen from serum of healthy donors (Ctrl) and patients 
diagnosed with gastritis (Gast), complete (MIC) and incomplete (MII) intestinal metaplasia isolated by lysine-sepharose 
affinity chromatography and b) nano-HPLC-MALDI-MS fraction of permethylated sialyl-Tn from plasminogen of 
patients with incomplete metaplasia intestinal exhibiting [M+Na]
+
 and c) MALDI-TOF/TOF spectra of [M+Na]
+
 
permethylated sialyl-Tn with unique fragmentations according to the nomenclature of Domon and Costello (1988) [1]. 
“*” signals resulting from the combination of cross-ring and glycosidic bound fragmentations occurring at both the 
reducing and non reducing ends. 
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As mentioned in the chapter III, a bioinformatics survey was necessary for the selection of 
the chromatographic runs corresponding to sialylated TF-related antigens. This allowed the 
distinction of an ion at m/z 691.4 corresponding to the sodium adduct of sialyl-Tn antigen 
(Figure 1b) in the plasminogen isolated from gastritis and intestinal metaplasia. The 
assignment was further reinforced by the disappearance of the signal upon treatment of 
plasminogen with a α-neuraminidase. Moreover, the product ion spectrum of the ion at m/z 
691.4 exhibited glycosidic bond cleavages B, C and Z, and cross-ring fragmentations A 
and X (nomenclature according to Domon and Costello (1988) [1]) characteristic of sialyl-
Tn (Figure 1C), therefore confirming the presence of sialyl-Tn in plasminogen. In 
agreement with previous reports concerning the O-glycosylation of plasminogen [19-21], 
low abundant ions belonging to mono (m/z 873.5 and 895.5) and disialylated (m/z 1234.7 
and 1256.6) -TF antigens have also been detected. 
 
CONCLUSION 
The sialyl-Tn is considered serum biomarker for advanced gastric cancer [22, 23] 
and is frequently associated with malignant phenotypes, aggressiveness, invasion, 
metastasization, and poor prognosis [24, 25]. This epitope has been further explored in 
cancer vaccines and as target for finding new tumor associated glycoproteins. Our western 
blot-based glycoproteomics studies have now unveiled that plasminogen forms carrying 
sialyl-Tn could be found in the serum of patients with pre-cancerous gastric lesions. In 
particular, cases with both incomplete and complete intestinal metaplasia have shown 
considerable expression of this aberrantly O-glycosylated form of plasminogen. This work 
has now confirmed blot assignments by mass spectrometry setting the structural basis for 
further studies directed to access the clinical value of this observation in the early 
diagnostic of gastric cancer.  
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The detection of sialylated oligosaccharides as well as sialylated glycoproteins have 
been widely studied. Several approaches have been presented, such as 
immunohistochemistry with antibodies [1] or lectins, but still structural validation is 
needed. In this context mass spectrometry is a high sensitive tool for the analysis of 
carbohydrates [2-4]. Since acidic glycans undergo metastable fragmentation in MALDI 
conditions [2-5], permethylation or similar derivatizing methods are often necessary to 
stabilize the sialic acids and unsure detection using this type of ionization [2, 6]. The  third 
chapter of this work was dedicated to the development a method for the analysis of a 
particular class of sialylated O-glycans, the TF-related antigens, frequently (over)expressed 
in cancer and other pathologies. The method relies on the release of O-glycans from 
proteins immobilized in SDS-PAGE gels by reductive β-elimination followed by 
permethylation and nanoLC-MALDI-TOF/TOF analysis. The MS data generated in this 
way was then analyzed by a bioinformatics survey for the ions of interest and combined in 
a sparse plot matrix such as the one presented in Figure 2 - chapter III. The information 
provided by these plots information was found crucial to distinguish chromatographic 
envelopes related with the targeted ions. Moreover it provided means to select 
chromatographic runs for MS/MS analysis. 
The proof of concept was achieved using fetuin, a widely studied glycoprotein, 
known to express sialyl-Tn, sialyl-3-T, sialyl-6-T and disialyl-T [7, 8]. All the above 
mentioned structures have been detected by our method having as starting material only 
low picomole of fetuin. To our knowledge, this is the first time that such low amounts of 
glycoprotein could be successfully screened for sialylated TF-related antigens.  
Noteworthy, this method allowed to differentiate the sialyl-6-T from sialyl-3-T based on 
their characteristic product ion spectra (Figure 4b and 5b).  
 The developed analytical approach was then successfully applied to the 
identification of tumor associated carbohydrate antigen sialyl-Tn in a glycoprotein isolated 
from the urine of rats with chemically-induced high-grade bladder tumors. Moreover, it  
permitted the identification of the same epitope in plasminogen isolated from the serum of 
patients with gastritis and intestinal metaplasia, a gastric cancer precursor lesions. Even 
though the clinical value of these observations warrants more investigations the structural 
bases have been accurately and undoubtedly set.  
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